LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC

ConclusionBased on this descriptive exploratory analysis, pembrolizumab plus pemetrexed and a platinum should be a standard first-line treatment for pts with metastatic non-squamous NSCLC regardless of KRAS mutation status. Table: LBA5With Any KRAS MutationWith KRAS G12C MutationWithout Any KRAS MutationPembro + Chemo (N  = 59)Placebo + Chemo (N = 30)Pembro + Chemo (N = 26)Placebo + Chemo (N = 11)Pembro + Chemo (N = 145)Placebo + Chemo (N = 55)ORR, % (95% CI)40.726.750.018.247.610.9(28.1-54.3)(12.3-45.9)(29.9-70.1)(2.3-51.8)(39.2-56.0)(4.1-22.3)PFS, median, mo (95% CI)9 (7-14)5 (5-9)11 (6-18) 5 (5-NR)9 (7-14)5 (4-5)PFS, HR (95% CI)0.47 (0.29-0.77)0.48 (0.22-1.06)0.40 (0.29-0.57)OS, median, mo (95% CI)21 (16-NR)14 (8-NR)18 (11-NR)25 (8-NR)23 (19-NR)9 (7-17)OS, HR (95% CI)0.79 (0.45-1.38)1.14 (0.45-2.92)0.55 (0.37-0.81)Clinical trial identificationKEYNOTE-189, NCT02578680.Editorial acknowledgementJoanne Tomassini and Melanie Leiby, both of Merck& Co., Inc., Kenilworth, NJ, USA, for writing support.Legal entity responsible for the studyMerck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.FundingMerck Sharp& Dohme Corp., a subsidiary of Merck& Co., Inc., Kenilworth, NJ, USA.DisclosureS. Gadgeel: Advisory / Consultancy: Boehringer-Ingelheim; Advisory / Consultancy: Xcovery; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Novocure; Advisory / Consultancy, Travel / Accommodation / Expenses: Genentech...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research